Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

599 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Disclosing quantitative RT-PCR raw data during manuscript submission: a call for action.
Untergasser A, Hellemans J, Pfaffl MW, Ruijter JM, van den Hoff MJB, Dragomir MP, Adamoski D, Dias SMG, Reis RM, Ferracin M, Dias-Neto E, Marsh I, Kubista M, Fabbri M, Goel A, Slabý O, Knutsen E, Chen B, Negrini M, Mimori K, Pichler M, Papatriantafyllou M, Anfossi S, Schmittgen TD, Huggett J, Bustin S, Vandesompele J, Calin GA; HEROIC (tHe initiativE gRoup On qRT dIsClosure) Consortium. Untergasser A, et al. Among authors: pichler m. Mol Oncol. 2023 May;17(5):713-717. doi: 10.1002/1878-0261.13418. Epub 2023 Mar 27. Mol Oncol. 2023. PMID: 36916500 Free PMC article.
MicroRNAs as regulators of tumor metabolism.
Ruggieri F, Jonas K, Ferracin M, Dengler M, Jӓger V, Pichler M. Ruggieri F, et al. Among authors: pichler m. Endocr Relat Cancer. 2023 Jul 18;30(8):e220267. doi: 10.1530/ERC-22-0267. Print 2023 Aug 1. Endocr Relat Cancer. 2023. PMID: 37224081 Review.
MiR-4649-5p acts as a tumor-suppressive microRNA in triple negative breast cancer by direct interaction with PIP5K1C, thereby potentiating growth-inhibitory effects of the AKT inhibitor capivasertib.
Jonas K, Prinz F, Ferracin M, Krajina K, Pasculli B, Deutsch A, Madl T, Rinner B, Slaby O, Klec C, Pichler M. Jonas K, et al. Among authors: pichler m. Breast Cancer Res. 2023 Oct 6;25(1):119. doi: 10.1186/s13058-023-01716-2. Breast Cancer Res. 2023. PMID: 37803350 Free PMC article.
Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up.
Fluhrer H, Hutterer GC, Golbeck S, Stidl M, Niedrist T, Pichler R, Mischinger J, Seles M, Mannweiler S, Spiegelberg J, Bauernhofer T, Jost PJ, Ahyai S, Zigeuner R, Pichler M, Barth DA. Fluhrer H, et al. Among authors: pichler r, pichler m. Ther Adv Med Oncol. 2022 Nov 19;14:17588359221134065. doi: 10.1177/17588359221134065. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36425872 Free PMC article.
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Santoni M, Buti S, Myint ZW, Maruzzo M, Iacovelli R, Pichler M, Kopecky J, Kucharz J, Rizzo M, Galli L, Büttner T, De Giorgi U, Kanesvaran R, Fiala O, Grande E, Zucali PA, Kopp RM, Fornarini G, Bourlon MT, Scagliarini S, Molina-Cerrillo J, Aurilio G, Matrana MR, Pichler R, Cattrini C, Büchler T, Massari F, Seront E, Calabrò F, Pinto A, Berardi R, Zgura A, Mammone G, Ansari J, Atzori F, Chiari R, Bamias A, Caffo O, Procopio G, Sunela K, Bassanelli M, Ortega C, Grillone F, Landmesser J, Milella M, Messina C, Küronya Z, Mosca A, Bhuva D, Santini D, Vau N, Morelli F, Incorvaia L, Rebuzzi SE, Roviello G, Soares A, Bisonni R, Bimbatti D, Zabalza IO, Rizzo A, Mollica V, Sorgentoni G, Monteiro FSM, Battelli N, Bracarda S, Porta C. Santoni M, et al. Among authors: pichler r, pichler m. Eur Urol Oncol. 2024 Feb;7(1):102-111. doi: 10.1016/j.euo.2023.07.003. Epub 2023 Jul 21. Eur Urol Oncol. 2024. PMID: 37481365
[No title available]
[No authors listed] [No authors listed] PMID: 37891455
Combining targeted and systematic prostate biopsy improves prostate cancer detection and correlation with the whole mount histopathology in biopsy naïve and previous negative biopsy patients.
Mischinger J, Schöllnast H, Zurl H, Geyer M, Fischereder K, Adelsmayr G, Igrec J, Fritz G, Merdzo-Hörmann M, Elstner J, Schmid J, Triebl A, Trimmel V, Reiter C, Steiner J, Rosenlechner D, Seles M, Pichler GP, Pichler M, Riedl J, Schöpfer-Schwab S, Strobl J, Hutterer GC, Zigeuner R, Pummer K, Augustin H, Ahyai S, Mannweiler S, Fuchsjäger M, Talakic E. Mischinger J, et al. Among authors: pichler gp, pichler m. Front Surg. 2022 Oct 6;9:1013389. doi: 10.3389/fsurg.2022.1013389. eCollection 2022. Front Surg. 2022. PMID: 36277287 Free PMC article.
599 results